CorMedix Inc. (NASDAQ: CRMD) is a Healthcare company (Biotechnology) with a market capitalization of $371M. The Maz Rating grades it against the other companies in its sector.
CorMedix Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.67, CorMedix Inc. trades at 5.9x trailing earnings, 0.9x sales and 0.8x book value, with an EV/EBITDA of 0.9. Over the last twelve months it generated about $410M of revenue and $63M of net income. It runs a gross margin of 77.5%, an operating margin of 38.6% and a net margin of 15.5%. It shows return on equity of 14.5%, return on invested capital of 10.6% and a free cash flow yield of 82.6%. On the balance sheet: a debt-to-equity ratio of 0.31 and a current ratio of 2.43. Over the past 52 weeks the share price ranged from $4.63 to $13.02, with a beta of 1.48.
CorMedix Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 8 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.